|05:27 EDT||NVS||FDA granted Bexsero to be used in vaccination program at UCSB|
Novartis announced that its meningococcal serogroup B, or MenB, vaccine, Bexsero, will be used as part of a vaccination program at the University of California Santa Barbara, or UCSB, that will end on March 7. In the last three months, the FDA has approved the use of Bexsero twice in response to MenB outbreaks at U.S. college campuses. More than 5,000 students were vaccinated at Princeton University and 20,000 students will be offered vaccination at UCSB. Bexsero is the only licensed broad coverage vaccine approved in Europe, Canada and Australia to help protect against invasive meningococcal disease caused by serogroup B. It was approved for use in the US under a treatment Investigational New Drug designation. Andrin Oswald, Division Head, Novartis Vaccines said, "We will continue to work with the FDA to pursue a potential license for Bexsero in the U.S. to help fulfill this public health need."